Skip to main content

Table 11 Selected studies for AML therapy from 2020 ASH annual meeting

From: Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting

Abstract # Authors (reference) Study agents Phase NCT
27 Wang et al. [131] Gilteritinib III 02752035
333 Daver et al. [136] Gilteritinib, Venetoclax Ib 03625505
461 Pollyea et al. [137] Azacitidine, Venetoclax Sub study of III and Ib 02203773
02993523
636 Stein et al. [138] Enasidenib Sub study of II 03013998
330 Sallman et al. [143] Magrolimab Ib 03248479
331 Aldoss et al. [144] Flotetuzumab I 02152956
460 Ravandi et al. [145] Vibecotamab I 02730312
165 Abedin et al. [146] Lintuzumab Ac225 I 03441048